BioMotiv
6
27M
4
0.60
2
0.33
- Areas of investment
Summary
BioMotiv appeared to be the VC, which was created in 2012. The main department of described VC is located in the Cleveland. The company was established in North America in United States.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Aro Biotherapeutics. Among the most popular fund investment industries, there are Biotechnology, Therapeutics.
Considering the real fund results, this VC is 47 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 5 - 10 millions dollars are the general things for fund. The top activity for fund was in 2018.
The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are NYU Innovation Venture Fund, Johnson & Johnson Innovation, Innovate Indiana Fund.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 2
- Rounds per year
- 0.60
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (6)
- Therapeutics (3)
- Pharmaceutical (3)
- Medical (3)
- Health Care (2) Show 1 more
- Investments by region
-
- United States (3)
- United Kingdom (3)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Amphista Therapeutics | 17 Mar 2021 | Biotechnology, Biopharma | Early Stage Venture | 53M | United Kingdom, Scotland |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.